Aducanumab: What About the Patient?; Risk of Aneurysm Rupture After Stroke Thrombolysis

In the first part of the podcast, Dr. Gregg Day discusses the importance of patient participation in the decision-making process when considering the use of aducanumab for the treatment of Alzheimer disease with Dr. Ron Petersen, Director of the Mayo Clinic Alzheimer’s Disease Center. In the second segment, Dr. Andy Southerland talks with Dr. Jyri Virta about the risk of aneurysm rupture after thrombolysis in patients with acute ischemic stroke and unruptured intracranial aneurysms.